Protocolli GOIRC-sponsored in fase di discussione
GOIRC-01-2024 PRELUDE
Pembrolizumab plus lenvatinib in REcurrent ccRCC patients failing permbroLizUmab aDjuvant treatment - PRELUDE Trial
Centro Coordinatore: Terni
GOIRC-04-2024 CECYDE
A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial
Centro Coordinatore: Lucca
GOIRC-05-2024 PREMAR (osservazionale)
PREvalence and PREdictive role of bioMARkers in advanced/metastatic gastric or gastroesophageal junction cancer patients: A multicenter prospective Observational Study – PREMAR
Centro Coordinatore: Reggio Emilia
GOIRC-07-2024 RESCUE
A multicenter, open-label, randomized phase III trial investigating the efficacy of Cemiplimab combined with histology-driven chemotherapy as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50% showing primary resistance to first-line immunotherapy
Centro Coordinatore: Bologna